Amphetamine

Monoamine Oxidase Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Health, Pharmaceutical, Psychoactive drugs, Monoamine oxidase inhibitors, Drugs, Amphetamine, Antidepressants, Hydrazines, Reversible inhibitors of MAO-A, Monoamine neurotransmitter, Monoamine oxidase, Tetrindole, Luteusin A

The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Monoamine Oxidase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Monoamine Oxidase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Drug Relieves Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults with ADHD

Retrieved on: 
Tuesday, June 29, 2021
Attention deficit hyperactivity disorder, Psychiatry, Childhood psychiatric disorders, Branches of biology, Abnormal psychology, Educational psychology, Amphetamine, Methylphenidate, Sluggish cognitive tempo, Adult attention deficit hyperactivity disorder, Stimulant, Attention deficit hyperactivity disorder controversies

Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.

Key Points: 
  • Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.
  • The NYU Langone-Mount Sinai team's findings, he adds, are the first to show that such treatments also work in adults.
  • "These findings highlight the importance of assessing symptoms of sluggish cognitive tempo and executive brain function in patients when they are initially diagnosed with ADHD," says Adler.
  • Researchers then carefully tracked their psychiatric health on a weekly basis through standardized tests for signs and symptoms of sluggish cognitive tempo, ADHD, as well as other measures of brain function.

Trilliant Health Analysis Projects Flat to Declining Future Demand for Health Services, With Increasing Supply from New Market Entrants like Amazon and Walmart

Retrieved on: 
Monday, June 28, 2021
Managed care, Other Health, Radiology, Pharmaceutical, Oncology, Mental health, Medical devices, Hospitals, Surgery, Medical Supplies, Practice Management, Health, Physical therapy, Articles, Retailers, Retailing, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Telehealth, Walmart

Moreover, future demand will not be meaningfully impacted by COVID-19 or by the increasing obesity of Americans, but primarily by population migration.

Key Points: 
  • Moreover, future demand will not be meaningfully impacted by COVID-19 or by the increasing obesity of Americans, but primarily by population migration.
  • The implications of softening demand and increasing supply suggest that pricing trends are ultimately unsustainable.
  • In addition, these trends confirm a key, but unreported, finding of the AAMC: the projected demand for surgeons has been declining for years.
  • Supply is rapidly increasing in commodity service offerings such as telehealth and urgent care, with new market entrants like Amazon and Walmart disrupting legacy delivery models.

DayTwo’s Solution for Obesity Delivers Sustained Weight Loss, BMI Reduction, and a Cost-Effective Alternative to Expensive Medications

Retrieved on: 
Thursday, June 24, 2021
Other Consumer, Diabetes, Fitness & Nutrition, Biotechnology, Other Health, Managed care, Health, Consumer, General Health, Obesity, Body shape, Health, Clinical medicine, Bariatrics, Branches of biology, Amphetamine, Nutrition, Weight loss

DayTwos unique solution for metabolic disease has meaningful and sustained clinical outcomes for employers, health systems, and health plans enabling a path to remission.

Key Points: 
  • DayTwos unique solution for metabolic disease has meaningful and sustained clinical outcomes for employers, health systems, and health plans enabling a path to remission.
  • After one year, participants sustain remarkable results including an average of:
    19 lbs of weight loss, and
    3.3 point drop in BMI.
  • DayTwos precision nutrition solution is offered at a critical time, as rates of obesity continue to skyrocket in the U.S.
  • Our sustained weight loss and BMI reduction results show that we are helping employees reach a healthy weight and get off expensive medications, said Josh Stevens, president of DayTwo.

Cats and Dogs Might Have Gained the "Covid 15," But New Data Reveals a Pet Obesity Epidemic Existed Long Before Quarantine

Retrieved on: 
Monday, June 21, 2021
Animals, Taxa, Organisms, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Pet, Overweight, Dog, Obesity in pets

A wider look shines a spotlight on an even more concerning reality: diagnoses of overweight and obesity in cats and dogs have been occurring in epidemic proportions long before quarantine.

Key Points: 
  • A wider look shines a spotlight on an even more concerning reality: diagnoses of overweight and obesity in cats and dogs have been occurring in epidemic proportions long before quarantine.
  • "We want pet owners to know that you are not alone in managing your pet's weight.
  • It's clear from the data that many pets and their owners are struggling with this issue and Banfield is here to help."
  • Compared with pets of ideal weight, dogs and cats diagnosed as overweight or obese are more likely to suffer from other serious conditions.

Adlon Therapeutics L.P. Announces Publication of Data from Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Studies Examining Sleep Quality Outcomes in CNS Drugs

Retrieved on: 
Monday, June 14, 2021
General Health, Other Health, Health, Science, Research, Psychoactive drugs, Stimulants, Psychiatric diagnosis, Nootropics, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, Insomnia, XR, Attention deficit hyperactivity disorder management, Adhansia XR®, Adlon Therapeutics L.P., ADHANSIA XR®, ADLON THERAPEUTICS L.P.

The studies evaluated the effect of Adhansia XR on sleep in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Key Points: 
  • The studies evaluated the effect of Adhansia XR on sleep in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
  • The most common sleep-related adverse events (AEs) in the double-blind study were headache (Adhansia XR, 17.5%; placebo, 11.5%), insomnia (Adhansia XR, 15.8%; placebo, 3.8%) and decreased appetite (Adhansia XR, 11.1%; placebo, 2.6%) for all doses combined.
  • Adhansia XR capsules contain identical beads which are formulated using the proprietary smart design MLR (Multi-Layer Release) technology.
  • Adhansia XR is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Adhansia XR.

NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Retrieved on: 
Monday, June 14, 2021
Articles, Health sciences, Health, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Medication, Wellness

Figure 1:NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Key Points: 
  • Figure 1:NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
    To view an enhanced version of Figure 1, please visit:
    H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference Details:
    The Company's presentation will be available on-demand at the start of the conference.
  • For more information regarding the conference or to schedule a one-on-one meeting with management, please contact KCSA Strategic Communications at [email protected] or your H.C. Wainwright representatives directly.
  • NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness.
  • In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity.

New Study Finds ADHD Test Serves as a Better Indicator of Medication Effects

Retrieved on: 
Tuesday, June 8, 2021
Mental health, Health, Science, Pharmaceutical, Research, Attention deficit hyperactivity disorder, Psychiatry, Childhood psychiatric disorders, Psychology, Amphetamine, Abnormal psychology, Methylphenidate, Psychiatric diagnosis, Attention deficit hyperactivity disorder controversies, Attention deficit hyperactivity disorder management

The Quantified Behavioral Test (QbTest), serves as a better early indicator of treatment effects for ADHD, confirming that healthcare professionals can confidently use objective data alongside patient feedback regarding treatment effectiveness.

Key Points: 
  • The Quantified Behavioral Test (QbTest), serves as a better early indicator of treatment effects for ADHD, confirming that healthcare professionals can confidently use objective data alongside patient feedback regarding treatment effectiveness.
  • View the full release here: https://www.businesswire.com/news/home/20210608005305/en/
    Study finds ADHD test serves as a better early indicator of medication effects than rating scales (Graphic: Business Wire)
    Clinical ADHD treatment procedures typically involve self-rated evaluations of symptoms as a means for measuring medication effects in adults with ADHD.
  • At the first follow up, QbTests activity and inattention measures showed significant effect of medication, compared to ASRS, that indicated only moderate effect.
  • The study proves how important it is to have objective data when managing ADHD symptoms.

FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014

Retrieved on: 
Friday, June 4, 2021
Clinical medicine, Medicine, Health, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Overweight, Placebo, Management of obesity, Obesity in the United States

This under-the-skin injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.

Key Points: 
  • This under-the-skin injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.
  • "FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight."
  • Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received placebo.
  • In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received placebo.

ADHD Medications Associated with Reduced Risk of Suicidality in Children with Significant Behavioral Symptoms

Retrieved on: 
Friday, June 4, 2021
Psychiatry, Abnormal psychology, Psychology, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Amphetamine, Psychiatric diagnosis, Methylphenidate, Externalizing disorders, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

"Early diagnosis and treatment of behavioral symptoms with ADHD medication, particularly among children with severe externalizing symptoms, may serve not only to improve learning and behavior problems, but also to decrease suicidality risk."

Key Points: 
  • "Early diagnosis and treatment of behavioral symptoms with ADHD medication, particularly among children with severe externalizing symptoms, may serve not only to improve learning and behavior problems, but also to decrease suicidality risk."
  • The researchers found that children expressing suicidal tendencies had more externalizing symptoms and were more likely to receive ADHD medication than non-suicidal children.
  • However, among children who demonstrated significant externalizing behaviors, those taking ADHD medications had lesser odds for suicidality, suggesting a moderating role for ADHD medications in these children.
  • They found that children with high externalizing symptoms who were treated with ADHD medications at baseline were less likely to be suicidal one year later.